September 12, 2019 / 5:43 AM / 2 months ago

BRIEF-Novartis Says Data Shows Mayzent Can Help Patients With Secondary Progressive Sclerosis

Sept 12 (Reuters) - Novartis AG:

* NEW NOVARTIS DATA SHOW MAYZENT® CAN HELP PRESERVE MOBILITY FOR LONGER IN PATIENTS WITH SECONDARY PROGRESSIVE MULTIPLE SCLEROSIS (SPMS)

* NEW POST HOC STATISTICAL ANALYSIS OF PIVOTAL EXPAND STUDY AT ECTRIMS SHOWS THAT MAYZENT® (SIPONIMOD) CAN HELP PATIENTS KEEP THEIR MOBILITY FOR OVER FOUR YEARS LONGER ON AVERAGE

* FURTHER EXPAND ANALYSES DEMONSTRATE MAYZENT ALSO SIGNIFICANTLY REDUCED GREY MATTER VOLUME LOSS AT ONE AND TWO YEARS, A KEY DRIVER OF DISABILITY PROGRESSION AND COGNITIVE DECLINE IN PATIENTS WITH SPMS

* ADDITIONAL PRE-CLINICAL DATA SHOW MAYZENT MAY HAVE RE-MYELINATION PROPERTIES, WHICH SUPPORT REGENERATION OF DAMAGED MYELIN IN CENTRAL NERVOUS SYSTEM, POTENTIALLY PREVENTING FURTHER NEURODEGENERATION

* MAYZENT, ONLY TREATMENT FOR ACTIVE SPMS APPROVED BY US FOOD AND DRUG ADMINISTRATION (FDA) WITH PROVEN EFFICACY IN A PIVOTAL STUDY OF A REPRESENTATIVE SPMS POPULATION, IS CURRENTLY UNDER REVIEW BY EUROPEAN MEDICINES AGENCY (EMA) Further company coverage: (Berlin Speed Desk)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below